Data from Pharmawand - Curated by Toby Galbraith - Date added 13 September 2017

Allergan plc has announced new head-to-head data from an open label study in Chronic Migraine in 282 patients, demonstrating that Botox (onabotulinumtoxinA) had a more favorable tolerability profile than Topamax (topiramate). Of patients randomized to receive topiramate, 50.7% of patients discontinued treatment due to adverse events, compared to 3.6% of patients randomized to receive onabotulinumtoxinA. Findings also show a significantly higher number of patients reported at least a 50% reduction in headache frequency when treated with onabotulinumtoxinA, compared to those treated with topiramate (40.0% vs 12.0%, p<0.001). These data, from the multi-center, prospective, open label FORWARD study, were presented for the first time today at the 18th Congress of the International Headache Society in Vancouver, Canada.

OnabotulinumtoxinA was generally well tolerated with 45.5% of patients reporting an adverse event (reported by more than 5% of any treatment group), the most common being sinusitis and neck pain – reported by 5.5% and 4.5% of patients, respectively. This compares with 76.8% of patients in the topiramate group, with paraesthesia, nausea and fatigue being the most common adverse events – reported by 31.0%, 13.4% and 13.4% of patients, respectively. Cognitive disorder was also reported in 12.7% of patients randomized to receive topiramate, compared to 0.5% of patients receiving onabotulinumtoxinA.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure


Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

Visit Hypogonadism

Related Content